Table 2.
Adverse events reported by checklist at baseline and at follow-up
| Symptom | Group | None | Mild | Moderate | Severe | P value |
|---|---|---|---|---|---|---|
| Rash | cART + EI-AED | 18 (90)/19 (95) | 2 (10)/1 (5) | 0 (0)/0 (0) | 0 (0)/0 (0) | 1.0 |
| cART-only | 38 (88)/38 (88) | 5 (12)/4 (10) | 0 (0)/0 (0) | 0 (0)/0 (0) | 0.743 | |
| Untreated | 73 (89) | 7 (9) | 2 (2) | 0 (0) | – | |
| Diarrhea | cART + EI-AED | 17 (85)/18 (90) | 3 (15)/2 (10) | 0 (0)/0 (0) | 0 (0)/0 (0) | 0.577 |
| cART-only | 36 (84)/36 (84) | 6 (14)/2 (10) | 1 (2)/1 (2) | 0 (0)/0 (0) | 1.0 | |
| Untreated | 67 (82) | 13 (16) | 2 (2) | 0 (0) | – | |
| Nausea or Vomiting | cART + EI-AED | 19 (95)/14 (70) | 1 (5)/4 (20) | 0 (0)/2 (2) | 0 (0)/0 (0) | 0.049 |
| cART-only | 39 (91)/36 (83) | 4 (9)/5 (12) | 0 (0)/2 (5) | 0 (0)/0 (0) | 0.133 | |
| Untreated | 67 (54) | 14 (17) | 1 (1) | 0 (0) | – | |
| Abdominal pain | cART + EI-AED | 16 (80)/15 (75) | 3 (15)/4 (20) | 1 (5)/1 (5) | 0 (0)/0 (0) | 0.789 |
| cART-only | 34 (79)/36 (84) | 8 (19)/6 (14) | 1 (2)/1 (2) | 0 (0)/0 (0) | 0.660 | |
| Untreated | 62 (76) | 16 (19) | 4 (5) | 0 (0) | – | |
| Dizziness | cART + EI-AED | 14 (70)/11 (55) | 5 (25)/8 (40) | 1 (5)/0 (0) | 0 (0)/1 (5) | 0.505 |
| cART-only | 33 (77)/30 (70) | 9 (21)/12 (28) | 1 (2)/1 (2) | 0 (0)/0 (0) | 0.522 | |
| Untreated | 65 (79) | 14 (17) | 3 (4) | 0 (0) | – | |
| Sleepiness | cART + EI-AED | 14 (70)/15 (75) | 5 (25)/4 (20) | 1 (5)/1 (5) | 0 (0)/0 (0) | 0.815 |
| cART-only | 35 (81)/40 (93) | 7 (16)/3 (7) | 1 (2)/0 (0) | 0 (0)/0 (0) | 0.057 | |
| Untreated | 63 (77) | 14 (17) | 5 (6) | 0 (0) | – | |
| Headache | cART + EI-AED | 6 (30)/14 (70) | 10 (50)/5 (25) | 3 (15)/2 (10) | 1 (5)/0 (0) | 0.007 |
| cART-only | 29 (67)/32 (74) | 13 (30)/10 (23) | 1 (2)/1 (2) | 0 (0)0 (0) | 0.555 | |
| Untreated | 49 (60) | 28 (34) | 5 (6) | 0 (0) | – | |
| Ataxia | cART + EI-AED | 15 (75)/16 (80) | 3 (15)/2 (10) | 1 (5)/1 (5) | 1 (5)/1 (5) | 0.789 |
| cART-only | 41 (95)/40 (93) | 2 (5)/3 (7) | 0 (0)/0 (0) | 0 (0)/0 (0) | 0.660 | |
| Untreated | 70 (85) | 11 (13) | 1 (1) | 0 (0) | – | |
| Blurred vision | cART + EI-AED | 19 (95)/18 (90) | 1 (5)/2 (10) | 0 (0)/0 (0) | 0 (0)/0 (0) | 0.577 |
| cART-only | 42 (98)/41 (95) | 1 (2)/2 (5) | 0 (0)/0 (0) | 0 (0)/0 (0) | 0.569 | |
| Untreated | 77 (94) | 5 (6) | 0 (0) | 0 (0) | – | |
| Weakness in arms or legs | cART + EI-AED | 13 (65)/12 (60) | 5 (25)/6 (30) | 1 (5)/2 (10) | 1 (5)/0 (0) | 1.0 |
| cART-only | 34 (79)/39 (91) | 8 (19)/4 (9) | 1 (2)/0 (0) | 0 (0)/0 (0) | 0.083 | |
| Untreated | 64 (78) | 18 (22) | 0 (0) | 0 (0) | – | |
| Numbness Tingling | cART + EI-AED | 15 (75)/19 (95) | 5 (25)/1 (5) | 1 (5)/0 (0) | 0 (0)/0 (0) | 0.104 |
| cART-only | 34 (79)/39 (91) | 8 (19)/4 (9) | 1 (2)/0 (0) | 0 (0)/0 (0) | 0.660 | |
| Untreated | 66 (80) | 12 (15) | 4 (5) | 0 (0) | – | |
| Generalized fatigue | cART + EI-AED | 9 (45)/16 (8) | 10 (50)/0 (0) | 0 (0)/4 (20) | 1 (5)/0 (0) | 0.204 |
| cART-only | 36 (83)/37 (86) | 5 (12)/6 (14) | 2 (5)/0 (0) | 0 (0)/0 (0) | 0.323 | |
| Untreated | 67 (82) | 13 (16) | 2 (2) | 0 (0) | – | |
| Problems Thinking | cART + EI-AED | 13 (65)/15 (75) | 4 (20)/3 (15) | 3 (15)/2 (10) | 0 (0)/0 (0) | 0.572 |
| cART-only | 40 (93)/41 (95) | 2 (5)/1 (2) | 1 (2)/1 (2) | 0 (0)/0 (0) | 0.277 | |
| Untreated | 74 (90) | 6 (7) | 2 (2) | 0 (0) | – | |
| Memory Problems | cART + EI-AED | 15 (75)/13 (65) | 5 (25)/6 (30) | 0 (0)/1 (5) | 0 (0)/0 (0) | 0.330 |
| cART-only | 36 (84)/29 (91) | 6 (14)/3 (7) | 1 (2)/1 (2) | 0 (0)/0 (0) | 0.445 | |
| Untreated | 65 (79) | 14 (17) | 3 (4) | 0 (0) | – | |
| Irritability/aggression | cART + EI-AED | 13 (65)/13 (65) | 3 (15)/5 (25) | 4 (20)/2 (10) | 0 (0)/0 (0) | 0.649 |
| cART-only | 35 (81)/36 (84) | 8 (19)/7 (14) | 0 (0)/0 (0) | 0 (0)/0 (0) | 0.710 | |
| Untreated | 61 (74) | 18 (22) | 3 (4) | 0 (0) | – | |
| Depression | cART + EI-AED | 13 (65)/12 (60) | 4 (20)/4 (20) | 3 (15)/4 (20) | 0 (0)/0 (0) | 0.666 |
| cART-only | 35 (81)/38 (88) | 8 (19)/3 (7) | 0 (0)/2 (5) | 0 (0)/0 (0) | 0.799 | |
| Untreated | 73 (89) | 6 (7) | 3 (4) | 0 (0) | – |
cART = combination antiretroviral therapy; EI-AED = cytochrome P450 enzyme-inducing antiepileptic drug. Data expressed as number endorsing symptom at initiation (%)/number endorsing symptom follow-up (%).